Tech Company Financing Transactions
BioVersys Funding Round
BioVersys, based in Basel, raised $35.4 million in investment from AMR Action Fund.
Transaction Overview
Company Name
Announced On
1/6/2023
Transaction Type
Venture Equity
Amount
$35,363,000
Round
Series C
Investors
AMR Action Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the clinical development of BV100, a potential hospital antibiotic targeting the most drug-resistant bacterial pathogen, Acinetobacter baumannii.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
c/o Technologiepark Hochbergerstrasse 60c
Basel, CH-4057
CH
Basel, CH-4057
CH
Phone
Website
Email Address
Overview
BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company's award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marc Gitzinger
Chief Financial Officer
Martin Bott
Chief Scientific Officer
Sergio Lociuro
Browse more venture capital transactions:
Prev: 1/6/2023: Cardiac Dimensions venture capital transaction
Next: 1/9/2023: Jackpot venture capital transaction
Share this article
News on VC Transactions
We record every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs